Option chain shows key data for ABVC BioPharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ABVC BioPharma.

ABVC BioPharma (NASDAQ:ABVC) Stock, Option Chain

ABVC BioPharma

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

Tesla stock

News

Pre-Market Outlook

Markets

Movers

ABVC

AEYE

BJDX

CSLR

CSSE

ENPH

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

NUKK

PEGY

TLSA

TRSG

TSLA

WIMI

ZPTA

Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

pharma lab worker ai

Penny Stocks

ABVC BioPharma said that the licensing agreement includes the ophthalmology pipeline, including the medical device Vitargus licensed products&#39; and clinical trial, registration, manufacturing, supply, and distribution rights.

Why ABVC BioPharma Stock Is Up Today

Small Cap

Intraday Update

Trading Ideas

ACET

AREN

ATIF

ATUS

ATXI

AVNS

FWBI

HKIT

JFBR

KROS

Kintara Therapeutics, Inc. - Common Stock

KTRA

LFMD

MBLY

MINM

MNSO

MOBX

MPLN

NEXI

NKLA

NMRD

NUZE

OMGA

PNST

RDUS

RLMD

SGLY

SMFL

XRTX

YCBD

Shares of  Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.&lt;

Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

ABVC BioPharma Inc

Health Care

Press Releases

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

Opinion

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

ABVC BioPharma's CEO Discusses New Drug Development and AI Integration

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

General

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

AMGN

CADL

CTMX

ONCY

TSX:ONC

BioAtla

BioVie

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Elevation Oncology

GlycoMimetics

HOOKIPA Pharma

Imunon

IN8bio

Leap Therapeutics

Lisata Therapeutics

Moleculin Biotech

MEI Pharma

Marker Therapeutics

Nanoviricides

NextCure

BiomX

Palatin Techs

SAB Biotherapeutics

Senti Biosciences

Spruce Biosciences

Synlogic

American BriVision Hldg

Comments

ABVC BioPharma

ABVC BioPharma (ABVC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga